Background and aims: Spontaneous bacterial peritonitis (SBP) is a severe complication of decompensated cirrhosis. The prevalence of multidrug-resistant organisms (MDROs) in patients with cirrhosis is increasing. Identification of patients at risk for SBP due to MDROs (ie, SBP with the evidence of MDROs or Stenotrophomonas maltophilia in ascitic culture, MDRO-SBP) is crucial to the early adaptation of antibiotic treatment in such patients. We therefore investigated whether MDROs found in ascitic cultures can also be found in specimens determined by noninvasive screening procedures. Patients and methods: This retrospective study was conducted at the liver center of the University Hospital Frankfurt, Germany. Between 2011 and 2016, patients with cirrhosis were included upon diagnosis of SBP and sample collection of aerobic/anaerobic ascitic cultures. Furthermore, the performance of at least one complete MDRO screening was mandatory for study inclusion. Results: Of 133 patients diagnosed with SBP, 75 (56.4%) had culture-positive SBP and 22 (16.5%) had MDRO-SBP. Multidrug-resistant Escherichia coli (10/22; 45.5%) and vancomycinresistant enterococci (7/22; 36.4%) resembled the major causatives of MDRO-SBP. Rectal swabs identified MDROs in 17 of 22 patients (77.3%) who developed MDRO-SBP with a time-dependent sensitivity of 77% and 87% after 30 and 90 days upon testing, while negative predictive value was 83% and 76%, respectively. The majority of patients were included from intensive care unit or intermediate care unit. Conclusion: MDRO screening may serve as a noninvasive diagnostic tool to identify patients at risk for MDRO-SBP. Patients with decompensated cirrhosis should be screened for MDROs from the first day of inpatient treatment onward. Keywords: multidrug resistance, liver cirrhosis, ascites, screening routine, antibiotic therapy
Introduction
The prevalence of multidrug-resistant organisms (MDROs) in patients with cirrhosis is rapidly increasing.
1,2 Bacterial infections have a devastating clinical impact in patients with decompensated cirrhosis, including prolonged and repeated hospitalization as well as reduced survival. [3] [4] [5] Spontaneous bacterial peritonitis (SBP) is the second most common bacterial infection in patients with cirrhosis and ascites. 6 Studies from different continents have determined cirrhotic patients' outcome as particularly poor in the case of infection by MDROs. 2, 3, [7] [8] [9] [10] [11] [12] [13] MDRO-mediated infections in cirrhosis have mostly been attributed to multidrug-resistant gram-negative bacteria (MDRGN). 14, 15 Secondary SBP prophylaxis with fluoroquinolones has been recommended for more than 2 decades, but multidrug resistance narrows therapeutic options. [15] [16] [17] [18] In addition, non-fermenting gram-negative bacteria expressing multidrug resistance, such as Stenotrophomonas maltophilia, might bloom under recurrent administration of antimicrobials. 4, 19, 20 In addition, gram-positive pathogens such as enterococci are increasingly contributing to the poor prognosis of SBP, since patients with cirrhosis are at high risk to acquire vancomycin-resistant enterococci (VRE). 15, [21] [22] [23] The burden and spread of VRE are associated with extensive and repetitive antibiotic therapies. 24, 25 The occurrence of these pathogens is being promoted by intestinal dysbiosis, putting patients with cirrhosis at high risk for acquiring SBP by MDROs (ie, SBP with the evidence of MDROs or S. maltophilia in ascitic culture, MDRO-SBP). 19, 20 Among the entities of bacterial infection in cirrhosis, SBP is particularly harmful due to the late onset of symptoms, risk of recurrence and the wide spectrum of causative bacteria. 4, 10, 15, 21, 22, 26 To guarantee optimal patient care and, at the same time, minimize selective pressure on further MDRO development, an individualized antibiotic regimen based on concise patient-specific data may be warranted. Therefore, the anticipation of expectable pathogens would be vital. Since SBP is derived from the intestinal microflora, it seems feasible to investigate whether these pathogens may be detected earlier by noninvasive procedures. In this retrospective study, we assessed the diagnostic utility of rectal, nasopharyngeal and cutaneous MDRO screening in a cohort of patients with decompensated cirrhosis, and we described the microbiological characteristics and clinical impact of MDRO-SBP in a tertiary liver transplant center in Germany.
Patients and methods study characterization
This study was conducted at the liver transplant center at University Hospital Frankfurt (UHF), Germany. From an electronic database, we retrieved all cases coded as "acute peritonitis" (ICD codes such as K65.0, K65.8 and K65.9) from 2012 to 2016. We retrieved 419 cases in total, which are represented by 299 individuals receiving inpatient treatment in the given period. Inclusion criteria were as follows: 1) diagnosis of SBP as defined by polymorphonuclear leukocyte count of >250/µL in ascites in patients with cirrhosis. Patients were included upon the first SBP episode diagnosed at UHF. 2) Sample collection of at least one pair of aerobic/anaerobic ascitic cultures at the bedside at the time of diagnosis of SBP.
3) Complete MDRO screening (rectal, throat, skin, nose swabs). Exclusion criteria were as follows: patients with primary peritonitis or malignant ascites due to any abdominal metastases or peritoneal carcinosis. Biometric, clinical, laboratory and microbiological data as well as empiric antibiotic therapy were collected at the date of study inclusion. If more detailed patient characterization was deemed necessary, the corresponding data were retrieved at defined time points after study inclusion. All the patient data were retrieved from electronic patient charts. Importantly, further microbiological data were collected from study inclusion until death or lost to follow up, resulting in multiple microbiological test results for most patients.
Colonization, infection and case definition
If MDROs were detected only in rectal, throat or cutaneous swabs, patients were defined as "colonized". If the MDRO strain was detected only or additionally in ascites, blood, urine, bronchial or pleural secretion, bile, pus, wounds or surgical sites, on medical devices or catheters, the patient was classified as "infected" by the strain. "Nosocomial SBP" was defined as SBP diagnosed at least 3 days after hospitalization according to the current definition 27, 28 or as SBP acquired up to 7 days after the last hospital discharge. Sepsis was defined as suspected or evident bacterial infection combined with two of the following clinical parameters according to the quick sequential organ failure assessment (qSOFA) score 29 :
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Determination of burden and impact of MDRO in patients with sBP hemodynamic instability with systolic blood pressure below 100 mmHg (including patients receiving noradrenaline with systolic blood pressure >100 mmHg), respiratory rate >22/ min or PaCO 2 <32 mmHg and/or altered mental status.
screening for MDROs at UhF 
Definition of MDRO-SBP
MDRO-SBP was defined as SBP due to MDRGN, VRE and MRSA as well as due to S. maltophilia. Although S. maltophilia intrinsically exhibits a broad spectrum of antibiotic resistance, eg, against antibiotic resistance, eg against carbapenems, it does not genuinely qualify to be included in the collective term "MDRO". However, S. maltophilia, MDRGN, VRE and MRSA all require treatment with broad-spectrum antibiotics. We therefore decided to include S. maltophilia in the collective term "MDRO-SBP".
Definition of MDRGN
MDRGN were defined as Enterobacteriaceae with extendedspectrum ß-lactamase (ESBL) phenotype as well as Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii resistant against piperacillin, any third-or fourthgeneration cephalosporin and fluoroquinolone resistance (QR) ± CR. 31, 32 Detection of MDROs and molecular resistance analysis All laboratory procedures were performed under qualitycontrolled criteria (laboratory accreditation according to ISO 15189:2007 standards; certificate number D-ML-13102-01-00, valid through January 25, 2021). To identify MDRGN and VRE, rectal swabs were collected using culture swabs with Amies collection and transport medium (Hain Lifescience, Nehren, Germany) and streaked onto selective CHROMagar ESBL plates (Mast Diagnostica, Paris, France) and ChromID VRE agar (bioMérieux, Nürtingen, Germany), respectively. Species identification was performed by matrix-assisted laser desorption ionization-time-of-flight analysis (VITEK MS; bioMérieux). Antibiotic susceptibility testing was performed according to Clinical and Laboratory Standards Institute guidelines using VITEK 2 and/or antibiotic gradient tests (bioMérieux). In the case of gram-negative CR isolates, the detection of genes encoding carbapenemases was routinely performed via PCR analysis and subsequent sequencing including the bla genes for carbapenemases NDM, VIM, IMP, OXA-48 like, and KPC as well as OXA-23, OXA-24 and OXA-58 for Acinetobacter baumannii. 33, 34 For the detection of MRSA, moistened nasal swabs were inoculated on Brilliance MRSA Agar (Oxoid, Wesel, Germany), and identification and antimicrobial susceptibility testing were performed as described earlier. 
2050
Ferstl et al
Wilcoxon-Mann-Whitney U-test. Kaplan-Maier curve was employed for the display of comparative survival analysis, and Cox-Mantel chi-squared test was used for the calculation of HR and P-values. Considering the appearance of MDRO-SBP as the event of interest, fatal outcome due to sepsis and fatal outcome due to other causes than sepsis were defined as competing risks, using the Aalen-Johansen estimator. In case that death fatal due to sepsis was considered as the event of interest, fatal outcome due to other causes than sepsis was defined as competing risk. Independent-risk factors for death were calculated using the multivariate Cox regression model. For calculating unbiased sensitivity and specificity for censored data with competing risks, the method proposed by Blanche et al 35 was utilized.
Results
clinical characterization of the cohort
One hundred and thirty-three patients diagnosed with SBP between December 2011 and August 2016 were included in the analysis ( Figure S1 ). Of these, 72 (54.1%) were positive for MDRO colonization or infection in any location, while MDRO-SBP was diagnosed in 22 patients (16.5%). Biometric and laboratory parameters as well as liver scores (ChildPugh-Turcotte, MELD, CLIF-AD, ALBI) did not differ between patients with or without the detection of MDROs or MDRO-SBP, respectively. Clinical features of hepatic decompensation were equally distributed (Table 1) . MELD score and ICU admission at the time of SBP diagnosis were independent predictors of survival, and MELD, CLIF-AD and ALBI scores were higher in patients who died than those in patients who were lost to follow up (Table S1 ). Patients with MDRO-SBP were at increased risk of death (HR =2.17, P=0.007) and were more likely to develop lethal sepsis (HR =5.67, P<0.001). While MELD and CLIF-AD scores were marginally better in patients with culture-negative SBP, severe clinical courses due to bacterial infections were more frequent in patients with MDRO-SBP ( Figure 1 ). As calculated by multivariate regression, liver scores or clinical features were not associated with the occurrence of MDRO-SBP.
Microbiological characterization of the cohort
The first MDRO screening was performed before or upon study inclusion in 105/133 patients (78.9%) and in timely fashion in the rest of the patients, resulting in MDRO detection in the majority of patients ( Figure 2A and B 
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Determination of burden and impact of MDRO in patients with sBP assessing the occurrence of MDRO-sBP upon rectal screening Since SBP originates from the intestinal microflora, we reasoned that rectal MDRO screening might reveal causative to pathogens in patients with MDRO-SBP. Among all patients with MDRO-positive ascitic culture, the identical strain could be detected in other body compartments; rectal swabs being the most frequent localization with 17/22 cases (77.3%; Table 3 ). Rectal, cutaneous or nasopharyngeal screening identified the corresponding pathogens in 20/22 cases (90.9%). Of note, one of these did not undergo rectal MDRO screening. The estimated time-dependent probability for the occurrence of MDRO-SBP upon the first positive rectal MDRO screening was 11.5% (SE =2.8%) after 30 days and 12.5% (SE =3%) after 60 days, respectively. Time-dependent sensitivity of MDRO screening before the occurrence of MDRO-SBP was 77% after 30 days and 87% after 90 days, while negative predictive value (NPV) was 83% and 76%, respectively (Table S3; Figure S2 ).
antibiotic treatment and secondary prophylaxis
Standard empirical therapy for community-acquired SBP at UHF is intravenous ceftriaxone, while the standard of care for nosocomial SBP is a carbapenem such as meropenem or imipenem. Based on the individual microbial data, diverging antibiotic regimens may have been chosen, and inappropriate initial therapy resulted in decreased survival in 19/60 (31.7%) patients with culture-positive SBP (HR =1.92, P=0.014). Initial treatment of MDRO-SBP comprised of carbapenems e Death due to other reasons composed of liver failure (ten patients), multi-organ failure (six patients), lactic acidosis (five patients), gastrointestinal bleeding (four patients), bleeding other than gastrointestinal (six patients), respiratory failure (four patients), kidney failure (two patients), liver transplant failure and heart failure (one patient each). MDRO-SBP, SBP with the evidence of MDROs or S. maltophilia in ascitic culture. 
Discussion
The global incidence of MDRO-SBP, especially caused by pathogens expressing resistance to cephalosporins and fluoroquinolones, is a growing health threat. 36 We showed that accurate microbiological screening measures helped identify patients who developed MDRO-SBP. These patients are at high risk of death due to sepsis. Although the study was designed in a retrospective fashion, our findings are consistent and clinically substantial due to the following arguments.
First, patients with and without MDRO detection had similar baseline parameters, thus resembling a homogenous population in terms of the severity of disease. Second, survival was impaired if the initial empiric antibiotic therapy did not cover the indicated pathogens, which is in line with previous findings and shows that lethality was mainly associated with bacterial infections. 37, 38 Third, while liver scores and survival in patients with culture-negative SBP were comparable to culture-positive patients, lethal sepsis was less frequent (Table 1) .
Regarding patients with culture-negative SBP, one might argue that cases of ascitic MDRO presence might 
Of note, strains were detected only in ascitic cultures, and the abovementioned sites are given. One patient was excluded from the chart due to incomplete MDRO screening, resulting in 21 patients. 
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Determination of burden and impact of MDRO in patients with sBP have been missed in some of these patients. However, It is well known that the sensitivity of ascitic cultures is only around 50%, 18 a fact that is reflected by our findings and has to be dealt with throughout the management of SBP. Nevertheless, MDRO-SBP was exclusively detected in patients with carriage of MDROs in other body compartments as well, while patients negative for MDROs also had significantly less positive ascitic cultures (HR =0.07, P<0.001). Considering the significantly better outcome in regard of septic complications in these patients, who are regularly treated with ceftriaxone, these SBP cases have to be considered as nonresistant rather than resistant.
Time-dependent sensitivity of MDRO screening for developing MDRO-SBP was between 77% and 95% including a high NPV, while specificity of the test was only around 50% (Table S3) . Thus, negative MDRO screening might rule out MDRO-SBP with a high likelihood. Due to its low specificity and positive predictive value (PPV), though, repetitive diagnostic paracentesis including microbiological sample collection remains mandatory. Patients with nosocomial SBP should receive empiric antibiotic therapy according to local resistance patterns. 28 A more "narrow" antibiotic therapy might be justified if MDRO screening was negative, but prospective data are warranted. Notably, the first MDRO evidence was made by the time of diagnosis of MDRO-SBP in almost half of the patients, since no screening results had been available beforehand.
Based on these observations, the ascitic detection of MDROs resembles a major prognostic factor in patients with decompensated cirrhosis. 11, 36 Because these patients are afflicted by rapid deterioration and death, early MDRO detection is vital. 37, 38 Since directional spread of MDROs goes from the intestine or skin into the abdomen (and not vice versa), it would be appropriate to screen for MDRO colonization in patients with risk or even history of SBP. Our data give the first evidence that this approach might be valid in the clinical setting and suggest that MDRO screening should be conducted on the day of patients' admission. However, a study including a larger sample size of patients with MDRO-SBP is warranted.
Conclusion
Due to the retrospective design of the study, it must be stressed that prospective data are warranted to validate the accuracy of MDRO screening in association with MDRO-SBP. Therefore, general treatment recommendations cannot be made based on our findings. Furthermore, patients were mainly recruited from ICU/IMC. This translates into comparably high liver scores upon inclusion and an overall reduced survival during inpatient treatment as well as under secondary prophylaxis. 39 Yet, differences between patients with and without MDRO-SBP were significant and comprehensible. Importantly, microbiological resistance data might depend on local resistance patterns, which is reflected by a high proportion of VRE, and may therefore not be transferable unrestrictedly. However, our microbiological data are comparable to reports from other monocenter studies. 1, 2, [11] [12] [13] [14] 21, 22, 40 On a more general basis, we suggest a prospective multicenter setting to determine the long-term clinical impact of MDRO-SBP and the benefit of MDRO screening in patients with decompensated cirrhosis.
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Impact of multidrug-resistant organisms in spontaneous bacterial peritonitis 
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Determination of burden and impact of MDRO in patients with sBP From 9/133 patients undergoing liver transplantation in total, six patients underwent liver transplantation after study inclusion.
b Reasons for no prophylaxis in these patients were as follows: discharge to other hospital or rehabilitation clinic with ongoing intravenous antibiotic therapy (n=3), transfer to palliative care (n=3), recurring colitis from C. difficile (n=1) and unidentifiable (n=5). Excluded due to primary peritonitis, malignant ascites or lacking ascitic leukocyte differentiation (n=149) Figure S1 cOnsORT diagram of patients included in the study, analysis and subgroup analysis. Notes: One patient who admitted with MDRO-sBP caused by E. coli expressing esBl and QR did not undergo rectal MDRO swabs, since he had not been admitted to IcU/IMc and no regular MDRO screening was scheduled on normal wards. The patient was included due to ascitic MDRO detection and completion of cutaneous MDRO screening and was defined as MDRO negative in rectal screening. MDRO-SBP, SBP with evidence of MDROs or S. maltophilia in ascitic culture. Abbreviations: E. coli, Escherichia coli; ESBL, extended-spectrum ß-lactamase; ICU, intensive care unit; IMc, intermediate care unit; MDRO, multidrug-resistant organism; QR, fluoroquinolone resistance; SBP, spontaneous bacterial peritonitis; S. maltophilia, Stenotrophomonas maltophilia. 
